Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-25T13:40:19.325Z Has data issue: false hasContentIssue false
  • English
  • Français

Infective endocarditis developing early after percutaneous closure of a patent ductus arteriosus in a child using the Amplatzer Duct Occluder II

Published online by Cambridge University Press:  19 March 2020

Murat M. Yilmazer Open the ORCID record for Murat M. Yilmazer [Opens in a new window]  and
Timur Meşe
Murat M. Yilmazer*
Affiliation:
Department of Pediatric Cardiology, Izmir Dr. Behçet Uz Children’s Hospital, University of Health Sciences, İzmir35210, Turkey
Timur Meşe
Affiliation:
Department of Pediatric Cardiology, Izmir Dr. Behçet Uz Children’s Hospital, University of Health Sciences, İzmir35210, Turkey
*
Author for correspondence: M. M. Yilmazer, MD, Associate Professor, Department of Pediatric Cardiology, Izmir Dr. Behçet Uz Children’s Hospital, University of Health Sciences, İsmet Kaptan, Alsancak District, Sezer Doğan Street Number: 11, 35210 Konak/İzmir, Turkey. E-mail: drmuratmuhtar@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

A 10-month-old girl underwent patent ductus arteriosus closure with an Amplatzer Duct Occluder II. After 1 week, she was admitted to our emergency room with tachypnoea, fatigue, and fever. Consecutive blood cultures yielded vancomycin-sensitive Staphylococcus aureus. The patient was already receiving vancomycin, but the fever did not respond to this treatment. The device was successfully removed via left lateral thoracotomy.

Type
Brief Report
Information
Cardiology in the Young , Volume 30 , Issue 4 , April 2020 , pp. 591 - 593
Copyright
© The Author(s) 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Latson, LA, McManus, BM, Doer, C, Kilzer, K, Cheatham, JP.Endocarditis risk of the USCI patent ductus arteriosus umbrella for transcatheter closure of patent ductus arteriosus. Circulation 1994; 90: 2525–2528.CrossRefGoogle ScholarPubMed
Li, JS, Sexton, DJ, Mick, N, et al.Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633–638.CrossRefGoogle Scholar
Campbell, M.Natural history of persistent ductus arteriosus. Br Heart J 1968; 30: 4–13.CrossRefGoogle ScholarPubMed
Edelstein, S, Yahalom, M.Cardiac device-related endocarditis: epidemiology, pathogenesis, diagnosis and treatment - a review. Int J Angiol 2009; 18: 167–172.CrossRefGoogle ScholarPubMed
Nishimura, RA, Otto, CM, Bonow, RO, et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: e57–185.CrossRefGoogle Scholar
Pérez-Vázquez, A, Fariñas, MC, García-Palomo, JD, et al.Evaluation of the Duke criteria in 93 episodes of prosthetic valve endocarditis: could sensitivity be improved? Arch Intern Med 2000; 160: 1185–1191.CrossRefGoogle ScholarPubMed
Habib, G, Lancellotti, P, Antunes, MJ, et al.2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36: 3075–3128.CrossRefGoogle Scholar
Saint-Andre, C, Iriart, X, Ntsinjana, H, Thambo, JB.Residual shunt after ductus arteriosus occluder implantation complicated by late endocarditis. Circulation 2012; 125: 840–842.CrossRefGoogle ScholarPubMed
Peng, C, Yang, W, Liu, G.Residual shunt and infective endocarditis after percutaneous device closure for patent ductus arteriosus. Int J Clin Exp Med 2017; 10: 1420–1423.Google Scholar
Sandoe, JA, Barlow, G, Chambers, JB, et al.Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint working party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and Britsih Society for Echocardiography (BSE). J Antimicrob Chemother 2015; 70: 325–329.CrossRefGoogle Scholar